Have a feature idea you'd love to see implemented?
Let us know!
IOVA Iovance Biotherapeutics Inc
Price (delayed)
$8.24
Market cap
$2.51B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.49
Enterprise value
$2.42B
Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy
Highlights
IOVA's revenue has soared by 177% QoQ
The gross profit has soared by 155% from the previous quarter
The company's quick ratio fell by 19% QoQ and by 17% YoY
Key stats
What are the main financial stats of IOVA
Market
Valuations
Earnings
Shares outstanding
304.78M
Market cap
$2.51B
Enterprise value
$2.42B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.23
Price to sales (P/S)
27.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.63
Revenue
$90.86M
EBIT
-$416.14M
EBITDA
-$374.51M
Free cash flow
-$374.08M
Per share
Balance sheet
Liquidity
EPS
-$1.49
Free cash flow per share
-$1.23
Book value per share
$2.55
Revenue per share
$0.3
TBVPS
$2.26
Total assets
$991.12M
Total liabilities
$217.66M
Debt
$78.94M
Equity
$773.46M
Working capital
$380.52M
Debt to equity
0.1
Current ratio
4.22
Quick ratio
3.89
Net debt/EBITDA
0.24
Margins
Efficiency
Dividend
EBITDA margin
-412.2%
Gross margin
8.9%
Net margin
-451.3%
Operating margin
-473.2%
Return on assets
-45.5%
Return on equity
-58.4%
Return on invested capital
-99.8%
Return on capital employed
-47.7%
Return on sales
-458%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IOVA stock price
How has the Iovance Biotherapeutics stock price performed over time
Intraday
1.23%
1 week
-4.07%
1 month
-16.94%
1 year
59.38%
YTD
1.35%
QTD
-12.25%
Financial performance
How have Iovance Biotherapeutics's revenue and profit performed over time
Revenue
$90.86M
Gross profit
$8.04M
Operating income
-$429.96M
Net income
-$410M
Gross margin
8.9%
Net margin
-451.3%
IOVA's revenue has soared by 177% QoQ
The gross profit has soared by 155% from the previous quarter
The company's gross margin has surged by 120% QoQ and by 101% YoY
Iovance Biotherapeutics's net margin has soared by 99% YoY and by 66% from the previous quarter
Growth
What is Iovance Biotherapeutics's growth rate over time
Valuation
What is Iovance Biotherapeutics stock price valuation
P/E
N/A
P/B
3.23
P/S
27.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.63
The EPS has grown by 28% YoY and by 11% from the previous quarter
IOVA's price to book (P/B) is 40% less than its 5-year quarterly average of 5.4 and 21% less than its last 4 quarters average of 4.1
IOVA's equity is up by 15% year-on-year
IOVA's revenue has soared by 177% QoQ
The price to sales (P/S) is 97% lower than the last 4 quarters average of 945.2
Efficiency
How efficient is Iovance Biotherapeutics business performance
The ROS has soared by 99% YoY and by 66% from the previous quarter
Iovance Biotherapeutics's ROIC has increased by 32% YoY and by 17% from the previous quarter
The return on assets has increased by 19% year-on-year and by 10% since the previous quarter
The ROE is up by 18% year-on-year and by 10% since the previous quarter
Dividends
What is IOVA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IOVA.
Financial health
How did Iovance Biotherapeutics financials performed over time
The total liabilities is up by 22% YoY and by 11% from the previous quarter
The company's quick ratio fell by 19% QoQ and by 17% YoY
Iovance Biotherapeutics's debt is 90% less than its equity
IOVA's debt to equity is down by 17% YoY and by 9% from the previous quarter
IOVA's equity is up by 15% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.